Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a cancer therapeutics company, which does business as AVEO Oncology™, committed to discovering, developing and commercializing targeted cancer therapies to impact patients’ lives. Our product candidates are directed against important mechanisms or targets, known or believed to be involved in cancer. Our proprietary Human Response Platform™, a novel method of building preclinical models of human cancer, provides us with unique insights into cancer biology and is leveraged in the discovery and clinical development of our cancer therapeutics. On November 27, 2012, the U.S. Food and Drug Administration, or FDA, accepted for filing our New Drug Application, or NDA, for tivozanib, our lead product candidate, with the proposed indication for the treatment of patients with advanced renal cell carcinoma, or RCC. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-2.6 |
| Quarterly EPS Est: | -0.59 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
3.25 |
Data is provided by Zacks Investment Research

